Introduction
Karten and Rivier [1] published in 1986 a com prehensive report of G nR H analog design and sum marized structure function studies toward the de velopment of agonists and antagonists by many in vestigators. They emphasized rationale and perspec tive, and included a section on peptide-induced his tamine release of timely importance.
Schmidt et al. [2] reported the pivotal observation that an antagonist, [Ac-D-2-Nal\4FD -Phe2,DTrp3,D-Arg6]GnRH, caused in rats a transient edema of the face and extremities when the peptide was subcutaneously administered. On the basis of this and subsequent observations, it was concluded [1] that those antagonists of L H R H which were the most potent in causing histamine release had a structural combination of a basic D-amino acid in position 6 and Arg8 and a grouping of hydrophobic aromatic amino acids in the three positions of the N-terminus.
Abbreviations: D-3-Pal, D-3-pyridylalanine; D-pClPhe, dp-chlorophenylalanine; D-2-Nal, D-2-naphthylalanine; Cit, Citrulline; 6-Qal, 6-quinolylalanine; NicLys, Ne-nicotinoyllysine; a-MeArg, a-methylarginine; A O A , antiovuktory activity; L H R H , luteinizing hormone releasing hormone; G n R H , gonadotropin releasing hormone; Boc, N-testbutoxycarbonyl.
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Verlag der Zeitschrift für Naturforschung, D-7400 Tübingen 0341 -0382/86/1100 -1087 $01.30/0 At this stage of the multidisciplinary and multiple group search for safe and effective antagonists of L H R H to control ovulation, it became compelling to design antagonists which not only would be ade quately potent but cause negligible release of his tamine which perhaps could be no greater than that of the clinically important superagonists of L H R H .
The release of histamine is not restricted to these antagonists of L H R H since somatostatin analogs caused histamine secretion [3] , and neuropeptides caused histamine release and vascular changes [4] , and compound 48/80 and substance P induced release of histamine and serotonin [5] , and gastrin induced histamine release from human cutaneous mast cells [6] , Subsequent to the realization that designs of an tagonists of L H R H must maintain potency of A O A and minimize histamine release, progress has been reported. Prominent in design change has been dele tion of D-Arg in position 6 and transfer of Arg in the L-form to position 5. Roeske et al. [7] synthesized [Ac-D-2-Nal1,4ClD-Phe2,D-Trp3,Arg;',D-Trp6,D-A la10]GnRH and found that it was about one-tenth as potent as the D-Arg6 antagonist in causing his tamine release.
Folkers et al. [8] 
Experimental

Materials
The purchase of the amino acid intermediates, the protective groups of the alpha-amino functions, the source and nature of the resin, solvents, and other chemicals were described [8] , but with modifications as follows.
Boc £-Nicotinoyl-lysine (NicLys), Boc-N-a-methyl-arginine (a-MeArg), and 6-Quinolylalanine (6-Qal) were synthesized. L-Citrulline was purchased from Aldrich and Boc protection of the alpha-amino group was added before coupling.
Synthesis
The 26 peptides of Table I were synthesized as described [8] .
Purification and purity
All of the peptides were first purified by chromatography over silica gel, and finally by HPLC using the solvent systems which were described [8] . Single peaks were observed on analytical |a-Bondpak C 18 columns (3.9 mm x 30 cm) when phosphateacetonitrile buffer systems were used at the various concentrations of acetonitrile according to Table II . The chromatographic data on these peptides are in Table II. Table III contains the amino acid analytical data, which were obtained as described [8] .
Biological assays
The peptides were bioassayed to determine their activities to inhibit ovulation in rats as described [8] , and the data are in Table I . Hook et al. [11] de scribed a system to assay analogs for histamine re lease, which we have used to provide the data in Table I . The system utilizes mast cells from adult male Sprague-Dawley rats. A concentration of 575 (ig/ml of L H R H in this system released 50% of the total histamine. Table I contains the data on the antiovulatory ac tivities and the activities for the release of histamine by the 26 peptides. Only two of the Peptides showed no antiovulatory activity (A O A ) at a dosage of 1 ^g. It was policy not to test the peptides above this level. Frequently, these peptides would not be tested at a level above 0.5 [A g in recognition of the goal which was to seek ever increasing potency. In general, the release of histamine was tested at a dosage of 10 ng unless a peptide was of special interest in which case the dosage was reduced to 0.01 ^g.
Results and Discussion
Activities for inhibition of ovulation in rats
All of these peptides have the substitutions of
Two objectives on sequence-activity were em phasized in the design of these 26 peptides which were to compare analogs with Lys8 and Arg8 and to compare analogs with substitutions in positions 3, 5, 6, 7 and 8.
Comparison of analogs with Lys8 and Arg8
Antagonists 1-8 constitute four pairs of antago nists, each with Arg8 and Lys8 (i.e., 1 and 2, 3 and 4. etc.). For the pair 1 and 2 and the pair 3 and 4, the Lys8 analogs were more potent than the Arg8 analogs (80% vs. 57%/0.25 ^g and 87% vs. 25%/0.5 ^ig, re spectively). For the 5 and 6, the potencies of the Lys8 and Arg8 analogs were similar (90% vs. 85%/1.0 |ig), but for the pair 7 and 8, the Lys8 analog was 1/2 as active as the Arg8 analog (50% vs. 100%/0.5 |ig). The first three pairs were identical except for Lys8 and Arg8, but each of the three pairs are different in position 6 which makes the comparisons more mean ingful. In the fourth pair. Arg was in position 5 in contrast to Tyr"' in the first three pairs. The most potent antagonist of Table I was peptide 7 with Arg5 and Arg8 which showed 60% A O A at 0.125 pig [8] . However, peptides 2 and 7 had similiar potencies (80 and 85%) at 0.25 jig. Again, a given substitution may be superior in one pair of analogs but not in another pair with only a single additional change. 
Comparisons of analogs with substitutions in
Activity for release of histamine
It is understood that the bioassays for A O A are presumably more quantitative than are the assays for the release of histamine by the method used. O f the four pairs of antagonists with Arg8 and Lys8, three of the four pairs with Lys8 were possibly less active for release of histamine than those with Arg8, but the reverse was probably true for the fourth pair (pep tides 7 and 8).
The two peptides (No. 2 and 7) showing 80 and 85% A O A , respectively, at 0.25 ng were less active for histamine release (158 and 120 mm) than was analog 9 which showed 100% AOA/O.25 ^g and a wheal area of 189 mm. 
